Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age

by Melendez Baez, Ivan , McPhee, Roderick , Yildirim, Inci , Ramirez Schrempp, Daniela , Creech, C. Buddy , Dunn, Michael , Girard, Bethany , Campbell, James D. , Miller, Jacqueline M. , Kirstein, Judith , Clifford, Robert A. , Berthaud, Vladimir , Anderson, Evan , Yut, Clifford , Das, Rituparna , Slobod, Karen , Zhao, Xiaoping , Atz, Andrew M. , Hautzinger, Kelly , Blair, Ronald , Deng, Weiping , Zhou, Honghong , Tomassini, Joanne E. , Pajon, Rolando , Pickrell, Paul , Schnyder Ghamloush, Sabine , Finkelstein, Daniel , Montefiori, David C.

in 2019-nCoV Vaccine mRNA-1273 - adverse effects / 2019-nCoV Vaccine mRNA-1273 - immunology / 2019-nCoV Vaccine mRNA-1273 - therapeutic use / Adolescent / Adolescent Medicine / Adult / Adverse events / Age / Age groups / Antibodies / Antibodies, Neutralizing - blood / Antibodies, Neutralizing - immunology / Antibodies, Viral - blood / Antibodies, Viral - immunology / Child / Childhood Diseases / Children / Coronavirus / Coronaviruses / COVID-19 - blood / COVID-19 - complications / COVID-19 - immunology / COVID-19 - prevention & control / COVID-19 vaccines / COVID-19 Vaccines - adverse effects / COVID-19 Vaccines - therapeutic use / Double-Blind Method / FDA approval / Heart diseases / Humans / Immune response / Immunization / Immunogenicity / Infections / Infectious Disease / Infectious diseases / Inflammation / Injection / Injections / mRNA / Multisystem inflammatory syndrome in children / Myocarditis / Original / Pediatrics / Pericarditis / Placebos / Population / Public health / Safety / SARS-CoV-2 / Severe acute respiratory syndrome coronavirus 2 / Systemic Inflammatory Response Syndrome / Teenagers / Vaccination / Vaccine Efficacy / Vaccines / Viral Infections / Young Adult / Young adults

2022

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age

2022

Confirm

Do you wish to request the book?

Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age

2022

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age

Melendez Baez, Ivan,

McPhee, Roderick,

Yildirim, Inci,

Ramirez Schrempp, Daniela,

Creech, C. Buddy,

Dunn, Michael,

Girard, Bethany,

Campbell, James D.,

Miller, Jacqueline M.,

Kirstein, Judith,

Clifford, Robert A.,

Berthaud, Vladimir,

Anderson, Evan,

Yut, Clifford,

Das, Rituparna,

Slobod, Karen,

Zhao, Xiaoping,

Atz, Andrew M.,

Hautzinger, Kelly,

Blair, Ronald,

Deng, Weiping,

Zhou, Honghong,

Tomassini, Joanne E.,

Pajon, Rolando,

Pickrell, Paul,

Schnyder Ghamloush, Sabine,

Finkelstein, Daniel,

Montefiori, David C.

2022

Overview

In part 1 of a phase 2–3 trial, a 50-μg dose of mRNA-1273 vaccine was safe and immunogenic. In part 2, nearly 4000 6-to-11-year-olds received two doses of vaccine or placebo and were followed for a median of 82 days. The vaccine had mainly mild adverse effects and was immunogenic in 99%, similar to the results in 18-to-25-year-olds. Vaccine efficacy during a delta-variant period was 88%.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

2019-nCoV Vaccine mRNA-1273 - adverse effects

/ 2019-nCoV Vaccine mRNA-1273 - immunology

/ 2019-nCoV Vaccine mRNA-1273 - therapeutic use

/ Adolescent

/ Adolescent Medicine

/ Adult

/ Adverse events